Codexis (CDXS) Projected to Post Quarterly Earnings on Thursday

Key Points

• Codexis is expected to report Q3 2026 results after market close on November 5, with analysts forecasting a loss of $0.0957 per share and revenue of $18.72 million.
• In the previous quarter, Codexis beat consensus estimates, reporting a $0.13-per-share loss versus expectations of $0.14 and revenue of $14.91 million versus $13.82 million expected.
• Shares opened at $1.26 and remain near their 12-month low, while analysts maintain a consensus “Hold” rating and a $6.50 price target; the company continues to operate at a loss with negative margins and return on equity.

Codexis (NASDAQ:CDXS - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.0957) per share and revenue of $18.72 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Codexis (NASDAQ:CDXS - Get Free Report) last released its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The firm had revenue of $14.91 million for the quarter, compared to analysts' expectations of $13.82 million. Codexis had a negative return on equity of 74.36% and a negative net margin of 39.55%. On average, analysts expect Codexis to post ($0.37) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Codexis Stock Down 1.6%

Shares of NASDAQ CDXS opened at $1.26 on Thursday. The company has a market cap of $137.98 million, a price-to-earnings ratio of -3.71 and a beta of 2.55. The company has a current ratio of 3.06, a quick ratio of 2.99 and a debt-to-equity ratio of 1.03. Codexis has a 12 month low of $0.96 and a 12 month high of $2.98. The stock has a 50-day moving average price of $1.42 and a two-hundred day moving average price of $1.81.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Piper Sandler decreased their price target on shares of Codexis from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Monday, August 17th. Weiss Ratings upgraded shares of Codexis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 23rd. Wall Street Zen downgraded shares of Codexis from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, Benchmark reissued a "hold" rating on shares of Codexis in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $6.50.

About Codexis

Codexis, Inc is a biotechnology company that develops enzymes and other biocatalytic technologies for use in pharmaceutical and biomanufacturing applications. Its proprietary CodeEvolver protein-engineering platform is designed to improve the performance of naturally occurring enzymes, including their activity, selectivity, stability and production characteristics.

The company works with pharmaceutical and biotechnology companies to develop biocatalysts used in the manufacture of active pharmaceutical ingredients, intermediates and other complex molecules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.